The investigation of lipoprotein-related phospholipase A2 (LP-PLA2) V279F mutation in coronary artery disease

Main Article Content

Hatice Yildirim Yaroglu
Nazli Akciger
Mehmet Ali Sungur
Dilek Cicek Yilmaz
Lulufer Tamer

Abstract

Aim: Despite advances in the treatment of cardiovascular diseases, coronary artery disease (CAD) is the leading cause of death worldwide. The media layer of normal and diseased arteries contains lipoprotein-associated phospholipase A2 (Lp-PLA2), which is mostly made by mast cells, T lymphocytes, and monocytes. Our research aimed to define how the Lp-PLA2 and V279F gene polymorphisms are related to CAD.


Materials and Methods: This study included 109 CAD patients and 71 controls. Fasting blood glucose (FBG) and lipid profiles were measured via the enzymatic colorimetric technique. Lp-PLA2 levels were detected with ELISA. The genomic DNAs were isolated from whole blood. Real-time polymerase chain reaction (RT-PCR) with the V279F mutation detection kit was used to identify the Lp-PLA2 V279F mutation. 


Results: In the CAD group compared to controls, serum Lp-PLA2 levels were higher (p 0.001). While FF (mutant) genotypes and VF (heterozygous) genotypes were absent in both groups, the Lp-PLA2 V279F mutation was discovered as the VV (wild) genotype in both the CAD group and controls.  


Conclusion: As a result, we determined that the Lp-PLA2 V279F mutation cannot be considered a genetic risk factor for CAD, but that Lp-PLA2 elevation may be an important parameter for CAD.

Downloads

Download data is not yet available.

Article Details

How to Cite
Yildirim Yaroglu, H., Akciger, N., Sungur, M. A., Cicek Yilmaz, D., & Tamer, L. (2023). The investigation of lipoprotein-related phospholipase A2 (LP-PLA2) V279F mutation in coronary artery disease. Annals of Medical Research, 30(10), 1217–1222. Retrieved from http://annalsmedres.org/index.php/aomr/article/view/4561
Section
Original Articles

Most read articles by the same author(s)